HANSOHPHARMA：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312025.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.Hansoh Pharmaceutical Group Company Limited翰 森 製 藥 集 團 有 限 公 司(Incorporated in the Cayman Islands with limited liability)(Stock Code:3692)ANNUAL RESULTS ANNOUNCEMENT FORTHE YEAR ENDED DECEMBER 31,2025The board(the“Board”)of director

3、s(the“Directors”)of Hansoh Pharmaceutical Group Company Limited(the“Company”)is pleased to announce the consolidated annual results of the Company and its subsidiaries(collectively,the“Group”)for the year ended December 31,2025(the“Reporting Period”),together with the comparative figures for the cor

4、responding period in 2024.In this announcement,“we”,“us”and“our”refer to the Company and the Group,depending on the context.FINANCIAL HIGHLIGHTSFor the year ended December 31,2025,the Group recorded the following audited results:Revenue was approximately RMB15,028 million,representing an increase of

5、 approximately 22.6%compared with the corresponding period of the previous year;Revenue of innovative medicines and collaborative products amounted to approximately RMB12,354 million,representing an increase of approximately 30.4%compared with the corresponding period of the previous year,and its pr

6、oportion of total revenue increased to approximately 82.2%;R&D expenditure was approximately RMB3,358 million,representing an increase of approximately 24.3%compared with the corresponding period of the previous year,and accounted for approximately 22.3%of the revenue;Profit for the year was approxi